Management of autoimmune temporal lobe epilepsy with GAD65 antibody: four case reports
Abstract
Aim of study. Glutamate decarboxylase (GAD) enzyme can be a target intracellular antigen in autoimmune focal epilepsy. GAD65 antibody is in found patients diagnosed with drug-refractory temporal lobe epilepsy (TLE). We explore the clinical features of the disease and therapeutic options.
Material and methods. We present the cases of four TLE patients, two of them with type 1 diabetes. All of them were drug-resistant and therefore underwent presurgical evaluation, which revealed GAD65 antibody positivity. We discuss the four GAD65 antibody positive temporal lobe epilepsy patients’ electroclinical data, the treatments, and their effectiveness.
Results. One of them became seizure-free after right anterior temporal lobe resection, two of them did not show significant improvement with immunmodulatory agents, and the fourth patient with the shortest duration of disease had significant improvement in seizure status and normalisation of cognitive status with IVIg therapy.
Conclusions and clinical implications. Our cases show that the earlier a GAD65 antibody is detected, the greater the chance of achieving seizure freedom or improvements in both seizure and cognitive status with immunomodulatory agents. However, in some cases, surgery may also bring seizure freedom, but with a risk of cognitive deterioration.
Keywords: GAD 65 antibodydrug-refractory epilepsyimmunomodulation in focal epilepsyautoimmune epilepsy
References
- Stagg CJ, Lang B, Best JG, et al. Autoantibodies to glutamic acid decarboxylase in patients with epilepsy are associated with low cortical GABA levels. Epilepsia. 2010; 51(9): 1898–1901.
- Steriade C, Britton J, Dale RC, et al. Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy: Conceptual definitions. Epilepsia. 2020; 61(7): 1341–1351.
- Malter MP, Helmstaedter C, Urbach H, et al. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol. 2010; 67(4): 470–478.
- Peltola J, Kulmala P, Isojärvi J, et al. Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology. 2000; 55(1): 46–50.
- Ariño H, Höftberger R, Gresa-Arribas N, et al. Paraneoplastic Neurological Syndromes and Glutamic Acid Decarboxylase Antibodies. JAMA Neurol. 2015; 72(8): 874–881.
- Daif A, Lukas RV, Issa NP, et al. Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy. Epilepsy Behav. 2018; 80: 331–336.
- Gómez CD, Buijs RM, Sitges M. The anti-seizure drugs vinpocetine and carbamazepine, but not valproic acid, reduce inflammatory IL-1β and TNF-α expression in rat hippocampus. J Neurochem. 2014; 130(6): 770–779.
- Kwan P, Sills GJ, Kelly K, et al. Glutamic acid decarboxylase autoantibodies in controlled and uncontrolled epilepsy: a pilot study. Epilepsy Res. 2000; 42(2-3): 191–195.
- Malter MP, Frisch C, Zeitler H, et al. Treatment of immune-mediated temporal lobe epilepsy with GAD antibodies. Seizure. 2015; 30: 57–63.
- Khawaja AM, Vines BL, Miller DW, et al. Refractory status epilepticus and glutamic acid decarboxylase antibodies in adults: presentation, treatment and outcomes. Epileptic Disord. 2016; 18(1): 34–43.
- Daif A, Lukas RV, Issa NP, et al. Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy. Epilepsy Behav. 2018; 80: 331–336.
- Mäkelä KM, Hietaharju A, Brander A, et al. Clinical Management of Epilepsy With Glutamic Acid Decarboxylase Antibody Positivity: The Interplay Between Immunotherapy and Anti-epileptic Drugs. Front Neurol. 2018; 9: 579.
- Carreño M, Bien CG, Asadi-Pooya AA, et al. Epilepsy surgery in drug resistant temporal lobe epilepsy associated with neuronal antibodies. Epilepsy Res. 2017; 129: 101–105.
- Mazzi G, Roia DDe, Cruciatti B, et al. Plasma exchange for anti GAD associated non paraneoplastic limbic encephalitis. Transfus Apher Sci. 2008; 39(3): 229–233.
- Widman G, Golombeck K, Hautzel H, et al. Treating a GAD65 Antibody-Associated Limbic Encephalitis with Basiliximab: A Case Study. Front Neurol. 2015; 6: 167.
- Dubey D, Alqallaf A, Hays R, et al. Neurological Autoantibody Prevalence in Epilepsy of Unknown Etiology. JAMA Neurol. 2017; 74(4): 397–402.
- Tröscher AR, Mair KM, Verdú de Juan L, et al. Temporal lobe epilepsy with GAD antibodies: neurons killed by T cells not by complement membrane attack complex. Brain. 2023; 146(4): 1436–1452.
